Table 1 Patient characteristics
Clinical characteristics | Exon 19 deletion (n=130) | Others (n=107) | p* | 1st generation TKI (n=177) | Afatinib (n=60) | p* |
|---|---|---|---|---|---|---|
Age, years | ||||||
 ≤70 | 86 (66.2%) | 65 (60.7%) | 0.417 | 101 (57.1%) | 50 (83.3%) | <0.0001 |
 >70 | 44 (33.8%) | 42 (39.3%) |  | 76 (42.9%) | 10 (16.7%) | |
Gender | ||||||
 Female | 75 (57.7%) | 63 (58.9%) | 0.895 | 115 (65.0%) | 23 (38.3%) | <0.0001 |
 Male | 55 (42.3%) | 44 (41.1%) |  | 62 (35.0%) | 37 (61.7%) | |
Smoking | ||||||
 No | 80 (61.5%) | 59 (55.1%) | 0.355 | 115 (65.0%) | 24 (40.0%) | 0.001 |
 Yes | 50 (38.5%) | 48 (44.9%) |  | 62 (35.0%) | 36 (60.0%) | |
ECOG PS | ||||||
 0/1 | 108 (83.1%) | 86 (80.4%) | 0.615 | 139 (78.5%) | 55 (91.7%) | 0.021 |
 ≥2 | 22 (16.9%) | 21 (19.6%) |  | 38 (21.5%) | 5 (8.3%) | |
Brain metastasis | ||||||
 No | 88 (67.7%) | 72 (67.3%) | 1.000 | 120 (67.8%) | 40 (66.7%) | 0.874 |
 Yes | 42 (32.3%) | 35 (32.7%) |  | 57 (32.2%) | 20 (33.3%) | |
Disease status | ||||||
 Recurrent | 20 (15.4%) | 18 (16.8%) | 0.859 | 27 (15.3%) | 11 (18.3%) | 0.549 |
 Primary metastatic | 110 (84.6%) | 89 (83.2%) |  | 150 (84.7%) | 49 (81.7%) | |
Type of EGFR mutation | ||||||
 Exon 19 deletion | - | - | - | 88 (49.7) | 42 (70.0) | 0.007 |
 Others | - | - |  | 89 (50.3) | 18 (30.0) | |
3rd generation TKI after PDa | ||||||
 Yes | 31 (25.0%) | 6 (6.2%) | <0.0001 | 23 (13.9%) | 14 (25.9%) | 0.058 |
 No | 93 (75.0%) | 90 (93.8%) |  | 143 (86.1%) | 40 (74.1%) | |